How wonderful to read such a positive and still realistic a post, Steamairship. The vast majority of biotechs would be far more painful and very much greater risk than CWE. 'We' also know that it going to work. With what efficiency, we don't know.
After a quick read of the HY Report I couldn't find anything we didn't know already except that cash in hand was $8.5 M. Anyone else?
Juke
- Forums
- ASX - By Stock
- Ann: Half Yearly Report and Accounts